Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$1.35 USD
-0.05 (-3.57%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ABOS 1.35 -0.05(-3.57%)
Will ABOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABOS
ABOS: Acumen Pharmaceuticals Cuts Clinical Trial Costs with Innovative Assay
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for ...
Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz